Inger is dedicated to leading an outstanding team of clinical research professionals. A graduate of the University of Arizona with a B.S. degree in biology and physics, Inger spent over a decade at Syntex, where she held roles of increasing responsibility in clinical operations. Inger directed trials for products in a wide range of health categories including infectious disease, cardiovascular, reproductive, anti-inflammatory, gastroenterology, rheumatology, CNS and dermatology. During her tenure, Inger managed Phase I-IV protocols and served on committees dedicated to improving Clinical Operations processes and innovation. After Roche acquired Syntex, she moved into global operations with the UK division of Roche, directing global HIV trials and managing the US based team.
In 1996, Inger partnered with Jodi Andrews to launch ProTrials. Their goal was straightforward: to provide clients with a team of highly experienced, dedicated, and detail-oriented clinical research professionals. Together, they have grown ProTrials into a multi-million dollar, global organization. With a 90 percent repeat customer base, ProTrials maintains a reputation for excellence and was recognized by CenterWatch as one of the fastest growing specialty CROs in North America. In addition to maintaining excellence, ProTrials is growing its capabilities in data management and biometrics, while continuing to expand globally.
Today, Inger brings over 30 years of industry experience to driving the company’s strategic direction. Both Inger and Co-CEO Jodi Andrews were named among Silicon Valley’s most influential businesswomen by the Silicon Valley Business Journal. Through Inger’s efforts, ProTrials was one of the first CROs in the country to adopt eco-sensitivity initiatives, resulting in its Green Business certification.